UnitedHealth Group Incorporated filings document the formal disclosures of a large health care company organized around UnitedHealthcare and Optum. Proxy materials describe board governance, executive compensation, shareholder voting matters and the company’s complementary businesses: UnitedHealthcare health coverage and Optum clinical, data, product, pharmacy and care services.
Current reports on Form 8-K cover operating and financial results, Regulation FD communications, strategy and market-position discussions, director appointments, compensation arrangements and other material-event disclosures. The filing record also documents governance practices, capital-structure and compensation matters, risk-related business context and the regulatory reporting framework for a Delaware public operating company in the health care sector.
UnitedHealth Group director reports small stock-related award. A UnitedHealth Group Inc. director reported receiving 13 shares of common stock on 12/16/2025 as dividend equivalents on vested deferred stock units, at a stated price of $0. These dividend equivalents vest immediately and follow the same terms as the underlying deferred stock units. After this transaction, the director holds 3,034 UnitedHealth Group shares directly, and additional indirect holdings of 2,146 shares through a revocable trust, 45 shares through one trust, and 55 shares through another trust.
UnitedHealth Group’s Chief Accounting Officer, Thomas E. Roos, reported an automatic increase in his holdings of company common stock. On 12/16/2025, he acquired 23.408 shares of common stock at a price of $0, coded as an acquisition, bringing his total directly held beneficial ownership to 29,642.927 shares.
The filing explains that these additional shares represent dividend equivalents credited on outstanding restricted stock units. These dividend equivalents follow the same vesting conditions as the underlying restricted stock units and will be forfeited if those units do not vest, meaning the added shares are still subject to performance or service-based requirements.
UnitedHealth Group Inc. (UNH) director reports initial ownership in a Form 3 filed under Section 16. As of the event date of 11/18/2025, the reporting person lists beneficial ownership of 0 shares of UnitedHealth Group common stock, held directly. No derivative securities are reported in the derivative securities table.
The form is filed by one reporting person in the capacity of director. A power of attorney is on file, with the Form 3 signed by Faraz A. Choudhry as attorney-in-fact for Scott M. Gottlieb.
UnitedHealth Group Incorporated reported that its Board of Directors has appointed Scott Gottlieb, M.D. as an independent director, effective immediately. He has not yet been assigned to any Board committees.
Dr. Gottlieb is a former FDA commissioner who served from 2017 to 2019, where he focused on transparency, patient safety, medical innovation, pharmaceutical competition, the opioid crisis and youth tobacco use. He has also held positions at the Centers for Medicare & Medicaid Services and on the Federal Health Information Technology Policy Committee, and is a physician, a member of the National Academy of Medicine, a senior fellow at the American Enterprise Institute and a partner at New Enterprise Associates.
Dr. Gottlieb currently serves on the boards of Pfizer, Inc., Tempus AI, Inc. and Illumina, Inc. He will receive the company’s standard compensation for non-employee directors as described in UnitedHealth Group’s 2025 proxy statement, and the company will enter into its standard indemnification agreement with him.
UnitedHealth Group amended its Amended and Restated Bylaws, effective November 6, 2025. The sole purpose of the change is to reflect updates to the Company’s registered office and registered agent in the State of Delaware.
A complete copy of the Bylaws, as amended, is filed as Exhibit 3.1.
UnitedHealth Group announced that senior leaders will participate in an interview at the UBS Global Healthcare Conference 2025. The session is scheduled for Monday, November 10, 2025, at 8:45 a.m. Eastern Time.
A live audio webcast will be accessible via the Investor Relations section of the company’s website. The disclosure is furnished under Item 7.01 (Regulation FD) and is not deemed filed under the Securities Exchange Act of 1934.
UnitedHealth Group (UNH) reported Q3 2025 results showing strong top-line growth but significantly lower profitability. Total revenues were $113.2 billion, up 12% year over year, driven by Medicare Advantage growth and Optum Rx volume. Diluted EPS was $2.59 versus $6.51 a year ago as medical costs rose faster than premiums.
Profitability compressed: the medical care ratio increased to 89.9% from 85.2%, reflecting Medicare funding reductions, higher care utilization, and seasonal impacts from the Inflation Reduction Act on Part D. Operating margin fell to 3.8% from 8.6% and earnings from operations declined 50% to $4.3 billion.
Segment trends: UnitedHealthcare revenue grew 16% with 795,000 more people served, primarily in Medicare Advantage. Optum revenues rose 8% (Optum Rx up 16%), while Optum Health profitability was pressured by Medicare dynamics and elevated cost trends. For the nine months, cash flows from operations were $18.6 billion, supporting ongoing dividends and repurchases disclosed in the period.
UnitedHealth Group (UNH) furnished an 8-K announcing its third quarter 2025 results. The company disclosed that it issued a press release detailing Q3 2025 performance, which is provided as Exhibit 99.1 and incorporated by reference.
The disclosure under Item 2.02 is expressly stated as furnished and not deemed filed under the Exchange Act. The filing also includes the Cover Page Interactive Data File labeled as Exhibit 104.
Frederick W. McNabb III, a director of UnitedHealth Group Inc. (UNH), reported receipt of 289 deferred stock units as compensation on 10/01/2025. The units were issued at $0 and are immediately vested but must be retained until he leaves the Board. Following the grant, Mr. McNabb beneficially owns 14,341 shares (direct). The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Timothy P. Flynn, a director of UnitedHealth Group Inc. (UNH), received 272 deferred stock units on 10/01/2025 as regular quarterly director compensation at a reported price of $0. The filing shows 9,810 shares beneficially owned following the transaction and an additional 6,033 shares held indirectly by trust. The form explains these deferred stock units are immediately vested but must be retained until the director leaves the board. The Form 4 was signed by an attorney-in-fact and dated 10/03/2025.